Table 6.

Follow-up data for patients with advanced HNC^a diagnosis on or after January 1, 2011.

Task			Data set A (n=7366)						Data set B (n=7754)
			Value, n		Value, median (IQR; range)		Value, mean (SD)		Value, n		Value, median (IQR; range)		Value, mean (SD)
Task 19: frequency of visits during target SACTb,c
	1Ld combination therapy	101		0.11 (0.07-0.16; 0.02-0.33)		0.13 (0.07)		19		0.17 (0.11-0.24; 0-0.36)		0.17 (0.09)
	1L monotherapy	358		0.05 (0.05-0.08; 0.01-0.50)		0.07 (0.05)		44		0.18 (0.09-0.22; 0-0.48)		0.16 (0.11)
	2L+e monotherapy	634		0.06 (0.05-0.10; 0.01-0.95)		0.08 (0.06)		106		0.13 (0.07-0.25; 0-0.75)		0.17 (0.14)
	All other	104		0.12 (0.09-0.17; 0.02-0.48)		0.14 (0.08)		76		0.14 (0.09-0.21; 0-1.3)		0.17 (0.17)
Task 20: for patients still alive, gap (in d) from the last target SACT administration and last visitf			708		28 (6-187; 0-1118)		128 (199)		167		70 (29-223; 0-1755)		159 (215)

^aHNC: head and neck cancer.

^bSACT: systemic anticancer therapy.

^cFrequency defined as number of visits between the first and last target SACT administration dates within the same LOT number and name, divided by number of days between the last and first target SACT administration.

^d1L: first line of therapy after the advanced HNC diagnosis date.

^e2L+: second-line or later therapy.

^fLimited to patients who (1) were still alive ≥180 days after last receipt of target SACT and (2) received last dose of target SACT ≥180 days before data cutoff on November 25, 2019 (thus on or before May 29, 2019).